Dissimilar Trypanosoma cruzi genotypespecific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorAlessio, Glaucia Diniz-
Autor(es): dc.creatorSilvestrini, Carolina Malheiros Araújo-
Autor(es): dc.creatorSantos, Silvana Maria Elói-
Autor(es): dc.creatorGontijo, Eliane Dias-
Autor(es): dc.creatorSales Junior, Policarpo Ademar Molina-
Autor(es): dc.creatorAvelar, Danielle Marchetti Vitelli-
Autor(es): dc.creatorAvelar, Renato Sathler-
Autor(es): dc.creatorWendling, Ana Paula Barbosa-
Autor(es): dc.creatorCarvalho, Andréa Teixeira de-
Autor(es): dc.creatorLana, Marta de-
Autor(es): dc.creatorMartins Filho, Olindo Assis-
Data de aceite: dc.date.accessioned2025-08-21T15:48:53Z-
Data de disponibilização: dc.date.available2025-08-21T15:48:53Z-
Data de envio: dc.date.issued2025-02-06-
Data de envio: dc.date.issued2025-02-06-
Data de envio: dc.date.issued2023-
Fonte completa do material: dc.identifierhttps://www.repositorio.ufop.br/handle/123456789/19720-
Fonte completa do material: dc.identifierhttps://doi.org/10.1371/journal.pntd.0012487-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1024769-
Descrição: dc.descriptionThe present study aimed to verify the impact of etiological treatment on the genotype-specific serological diagnosis of chronic Chagas disease patients (CH), using the Chagas-Flow ATE IgG1 methodology. For this purpose, a total of 92 serum samples from CH, categorized as Not Treated (NT, n = 32) and Benznidazole-Treated (Bz-T, n = 60), were tested at Study Baseline and 5Years Follow-up. At Study Baseline, all patients have the diagnosis of Chagas disease confirmed by Chagas-Flow ATE IgG1, using the set of attributes (“antigen/serum dilution/cut-off”; “EVI/250/30%”). The genotype-specific serodiagnosis at Study Baseline demonstrated that 96% of patients (44/46) presented a serological profile compatible with TcII genotype infection. At 5Years Follow-up monitoring, NT and Bz-T presented no changes in anti-EVI IgG1 reactivity. However, significant differences were detected in the genotypespecific IgG1 reactivity for Bz-T. The most outstanding shift comprised the anti-amastigote TcVI/(AVI), anti-amastigote TcII/(AII) and anti-epimastigote TcVI/(EVI) reactivities. Regardless no changes in the genotype-specific serology of NT (TcI = 6%; TcII = 94%), distinct T. cruzi genotype-specific sero-classification was detected for Bz-T samples at 5Years Followup (TcII = 100%) as compared to Baseline (TcII = 97%; TcVI = 3%). The anti-trypomastigote TcI/(TI) was the attribute accountable for the change in genotype-specific sero-classification. In conclusion, our findings of dissimilar T. cruzi genotype-specific serology upon Bztreatment re-emphasize the relevance of accomplishing the genotype-specific serodiagnosis during clinical pos-therapeutic management of chronic Chagas disease patients.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsaberto-
Direitos: dc.rightsThis is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Fonte: PDF do artigo.-
Título: dc.titleDissimilar Trypanosoma cruzi genotypespecific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.